Schedule 13G ownership disclosure
Tenax Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 88032L605
Event date: 2025-10-22
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 339,633.00 · Class: 7.4%
- Point72 Capital Advisors, Inc.
Shares: 339,633.00 · Class: 7.4%
- Steven A. Cohen
Shares: 339,633.00 · Class: 7.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-004624
- Form type
- SCHEDULE 13G
- Filer
- Point72 Asset Management, L.P.
- CIK
- CIK 1603466
- Filed
- Oct 29, 2025
- Reporting period
- Oct 22, 2025
- Description
- Schedule 13G beneficial ownership